HomeBUSINESS
BUSINESS

Blincyto OK Now in Hand, Amgen Astellas JV Revs Up for Foray into Japan Oncology Market
(Oct.4.2018)

Steve Sugino, President & Representative Director, Amgen Astellas BioPharma
Amgen Astellas Biopharma (AABP), a Japanese joint venture of the two namesake companies, is set to make inroads into the Japan oncology market as early as November with its leukemia drug Blincyto (blinatumomab), looking at further launches down the line to build up a cancer franchise as another business pillar alongside its specialty portfolio ...
(LOG IN FOR FULL STORY)